Daraxonrasib Improves Survival in Pancreatic Cancer Trial
A new targeted therapy nearly doubles median survival time for patients with metastatic pancreatic ductal adenocarcinoma.
Updated on Oct. 23, 2026 in Cancer
Phase 3 clinical trial data demonstrates that the drug daraxonrasib significantly extends life for patients with previously treated metastatic pancreatic ductal adenocarcinoma. The treatment achieved a median overall survival of 13.2 months compared to just 6.7 months for those receiving standard chemotherapy.
Why it matters
Pancreatic ductal adenocarcinoma is a highly aggressive cancer with limited treatment options, making these results a significant therapeutic advancement. The findings offer a new standard of care following the FDA approval of the drug in August 2026.
The RASolute 302 trial reported an overall survival hazard ratio of 0.42 for the 300 mg daily oral dose of daraxonrasib. The objective response rate reached 32 percent for the treatment group compared to 11 percent for the chemotherapy cohort.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
ESMO
The European Society for Medical Oncology is a prominent professional organization for medical oncology that hosts major scientific congresses.
The details
Patients in the study received either the oral daraxonrasib treatment or investigator-selected chemotherapy, with randomization stratified by performance status and mutational markers. Notably, 70 percent of participants in both trial arms presented with baseline liver metastases.
Timeline
May 29-June 2, 2026: Primary and final analysis of the RASolute 302 trial presented.
August 2026: FDA approved daraxonrasib for metastatic pancreatic ductal adenocarcinoma patients.
October 23-27, 2026: Subgroup analysis of the trial presented at the ESMO Congress.
The Big Picture
This study follows the precedent set by the RASolute 302 trial in targeting specific mutations within metastatic pancreatic ductal adenocarcinoma. The research marks a significant shift from broad-spectrum chemotherapy toward precision medicine in oncological care.
The clinical trial results provide a new pathway for patients diagnosed with metastatic pancreatic ductal adenocarcinoma to access targeted daily oral therapy. Patients should consult with their oncology care team regarding eligibility and potential access following the FDA approval.
The takeaway
Targeted therapies are increasingly becoming a viable alternative to traditional chemotherapy for complex pancreatic cancer cases. Patients and families are encouraged to discuss emerging trial data with specialists to understand the full range of modern treatment options.
Further reading
For more information on the current state of oncological research, visit the Cancer section.
More information
View the official FDA announcement for targeted therapy approval for further details.
